Date: 2017-12-12
Type of
information: Results
phase: preclinical
Announcement: results
Company: Neovacs (France)
Product: IFN alpha Kinoid
Action
mechanism:
- kinoid/immunotherapy product. A Kinoid is obtained by chemically linking the cytokine of interest to a foreign carrier protein, KLH ( Keyhole Limpet Hemocyanin), and then treating the resultant compound to inactivate the cytokine. These active immunotherapies have been designed to induce an antibody response (self-polyclonal antibodies) by the patient’s immune system that targets a particular over-expressed cytokine responsible for the pathogenesis and development of a given disease. The Kinoid technology can be applied in principle to any cytokine target.
Disease: type 1 diabetes
Therapeutic
area: Autoimmune diseases - Metabolic diseases
Country:
Trial
details:
Latest
news:
- • On December 12th 2017, Neovacs announced positive initial results from its ongoing proof-of-concept (PoC) preclinical studies with IFNalpha Kinoid for the treatment of type 1 diabetes (T1D).
The ongoing PoC preclinical studies in non-obese diabetic (NOD) mice, conducted in collaboration with Dr. Agnès Lehuen and Pr. Christian Boitard, from the department of Immunology of Diabetes at the Hospital Cochin in Paris, have confirmed:
– a strong production of neutralizing antibodies to IFN? following IFNalpha Kinoid administration
– twice higher preservation of Langerhans islets is observed in mice treated with IFNalpha Kinoid compared to the control groups.
– a notable delay in the onset of type 1 diabetes in relation to the persistence of anti-IFNalpha neutralizing antibodies.
Neovacs expects to complete this study in 2018 in order to fully evaluate the therapeutic potential of IFNalpha Kinoid in type 1 diabetes. These final results will guide the protocol of Neovacs’ first clinical study in this indication.
Is
general: Yes
